Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. 1994

S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
Department of Medicine, Tulane University Medical Center, New Orleans, LA.

To study its safety and efficacy in treating cytomegalovirus (CMV) retinitis, an AIDS patient received an intravitreal injection of liposome encapsulated ganciclovir in the right eye. The left eye served as a control, receiving intravitreal free ganciclovir. The right eye showed no retinal haemorrhages or detachment; however, vision declined initially, stabilising later. Weekly examination showed neither progression of the CMV retinitis nor new lesions in the right eye. The left eye showed reactivation of old CMV retinitis. Liposome encapsulated ganciclovir reduced the number of intravitreal injections, stabilising CMV retinitis, and warrants further study.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008297 Male Males
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015774 Ganciclovir An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. BIOLF-62,BW-759,Cytovene,Ganciclovir Sodium,Ganciclovir, Monosodium Salt,Gancyclovir,RS-21592
D017088 AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus. HIV-Related Opportunistic Infections,Opportunistic Infections, AIDS-Related,Opportunistic Infections, HIV-Related,AIDS Related Opportunistic Infections,AIDS-Related Opportunistic Infection,HIV Related Opportunistic Infections,HIV-Related Opportunistic Infection,Infection, HIV-Related Opportunistic,Infections, HIV-Related Opportunistic,Opportunistic Infection, AIDS-Related,Opportunistic Infection, HIV-Related,Opportunistic Infections, AIDS Related,Opportunistic Infections, HIV Related
D017726 Cytomegalovirus Retinitis Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness. Retinitis, Cytomegalovirus,Cytomegaloviral Retinitis,Retinitis, Cytomegaloviral

Related Publications

S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
August 1996, Nippon Ganka Gakkai zasshi,
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
January 1990, Presse medicale (Paris, France : 1983),
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
November 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
April 1996, Revista clinica espanola,
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
May 1988, Ophthalmology,
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
January 1996, The Annals of pharmacotherapy,
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
January 1992, The Annals of pharmacotherapy,
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
January 1987, Retina (Philadelphia, Pa.),
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
October 1988, Archives of ophthalmology (Chicago, Ill. : 1960),
S K Akula, and P E Ma, and G A Peyman, and M H Rahimy, and N E Hyslop, and A Janney, and P Ashton
June 1987, American journal of ophthalmology,
Copied contents to your clipboard!